Biogen: Key Takeaways From Needham’s Meeting With Top Management
Needham analyst Ami Fadia raised her price target on Biogen (NASDAQ: BIIB ) to $256 from $255 and maintained a Buy rating following a meeting with company management. Spinraza HD uptake has been “quite positive,” with demand matching Spinraza’s launch levels, driven by both new and returning patients, Fadia wrote. She